A STUDY ON HUMAN T CELLS BEARING IgG-Fc RECEPTOR IN PATIENTS WITH BLADDER TUMOR

Abstract

IgG-FcR⁺-T cell ratio was measured in 50 patients with bladder tumor as a parameter to estimate the cell mediated immunity before the treatment.
IgG-FcR⁺-T cell was detected by the double rosette method, employing sheep erythrocytes and rabbit IgG antibody coated chicken erythrocytes.
IgG-FcR⁺-T cell ratio in 50 patients with bladder tumor was 7.6±5.7% (mean±standard deviation), while that in controls consisting of 20 patients with other diseases but bladder tumor was 5.2±2.4%. There was no significant difference between them.
IgG-FcR⁺-T cell ratio in the group in early stages (pTa, pT1 & pT2) was 5.4±4.5%, and that in the group in advanced stages (pT3a, pT3b & pT4) was 10.8±6.0%. —significant difference between them (p<0.001)—.
IgG-FcR⁺-T cell ratio in the low graded group (G0 & G1) was 5.5±4.4% and that in the high graded group (G2 & G3) was 9.7±6.2%. —significant difference between them (p<0.01)—.
IgG-FcR⁺-T cell ratio in patients with the serum level of CEA over 2.6ng/ml was 12.5±6.3% and that under 2.5ng/ml was 5.6±3.7%. —significant difference between them (p<0.001)—.
In patients having IgG-FcR⁺-T cell ratio over 9%, there was a correlation between IgG-FcR⁺-T cell ratio and PHA-induced lymphocyte blastogenesis ratio (r=-0.81, p<0.01).
In patients with the serum level of CEA over 2.6%ng/ml, PHA-induced lymphocyte blastagenesis was decreased significantly and IgG-FcR⁺-T cell ratio was increased significantly.
These findings suggest that serum CEA may play a role to proliferate the IgG-FcR⁺-T cells in association with an inhibition of PHA-induced lymphocyte blastogenesis.